Opendata, web and dolomites

THERAPE SIGNED

Novel blood-brain barrier permeable CDNF-derived therapeutic peptides for the protection and regeneration of dopamine neurons

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 THERAPE project word cloud

Explore the words cloud of the THERAPE project. It provides you a very rough idea of what is the project "THERAPE" about.

neurotrophic    midbrain    homing    prof    tissues    variants    brain    barrier    generation    leader    patients    vitro    severe    parkinson    vivo    researcher    motor    microsurgery    cerebral    training    disciplines    interface    molecular    showed    master    mutated    world    lasting    trials    laboratories    animal    neurobiology    treat    hands    neurodegenerative    combines    connecting    leads    saarma    preliminary    tested    reverse    delivered    treatments    excellent    cdnf    models    relief    risky    pass    penetrate    holds    edge    avoiding    trained    blood    permeable    neurons    independent    santos    conjugated    stop    innovative    laakkonen    nanomedicine    bbb    breakthrough    penetration    clinical    fragment    expert    treatment    progressive    stability    scientists    group    length    nanoparticles    promises    slow    peptides    scientific    movement    shown    symptoms    neurodegeneration    intracranial    despite    possibility    pd    dopamine    systemic    feasibility    data    cutting    surgery    disease    disorders   

Project "THERAPE" data sheet

The following table provides information about the project.

Coordinator
HELSINGIN YLIOPISTO 

Organization address
address: YLIOPISTONKATU 3
city: HELSINGIN YLIOPISTO
postcode: 14
website: www.helsinki.fi

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Total cost 202˙680 €
 EC max contribution 202˙680 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-09-02   to  2022-05-03

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) coordinator 202˙680.00

Map

 Project objective

Parkinson's disease (PD) is the second most common neurodegenerative disease characterized by the progressive loss of midbrain dopamine neurons that leads to the severe movement disorders and several non-motor symptoms. Available PD treatments do not provide long-lasting relief from the symptoms and do not slow down or stop the neurodegeneration. Cerebral dopamine neurotrophic factor (CDNF) was shown to reverse the PD-associated neurodegeneration in vitro and in vivo in animal models. Currently, CDNF is tested in the phase I-II clinical trials in PD patients. Despite of the promising results, CDNF doesn’t pass through the blood brain barrier (BBB) and should be delivered to the brain of PD patients through the risky microsurgery. Thus, there is a great need for the CDNF variants that can penetrate through the BBB avoiding intracranial surgery. In addition, systemic delivery of BBB permeable CDNF would offer a possibility to treat non-motor symptoms. Current proposal combines the cutting-edge molecular neurobiology and nanomedicine to develop the next generation CDNF-derived peptides that will be able to penetrate the BBB. For that 1) the length of CDNF will be reduced to enable penetration through the BBB, 2) CDNF fragment will be mutated to improve its stability in the blood and tissues and 3) CDNF fragment will be conjugated to nanoparticles to increase its stability and ability to penetrate the BBB. Our preliminary data showed the feasibility of this approach and holds great promises for the breakthrough in the treatment of PD. In addition, during the project applicant will be trained into independent group leader through the hands-on training in the top scientific laboratories and by managing the highly innovative research at the interface of different disciplines connecting three excellent scientists: Prof. Saarma, the world leading molecular neurobiology researcher, Prof. Laakkonen, the expert in homing peptides and Prof. Santos, the master of nanomedicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERAPE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERAPE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MathematicsAnalogies (2019)

Mathematics Analogies

Read More  

MingleIFT (2020)

Multi-color and single-molecule fluorescence imaging of intraflagellar transport in the phasmid chemosensory cilia of C. Elegans

Read More  

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More